143 related articles for article (PubMed ID: 37382636)
1. The Fontan Udenafil Exercise Longitudinal Trial: Subgroup Analysis.
Goldberg DJ; Hu C; Lubert AM; Rathod RH; Penny DJ; Petit CJ; Schumacher KR; Ginde S; Williams RV; Yoon JK; Kim GB; Nowlen TT; DiMaria MV; Frischhertz BP; Wagner JB; McHugh KE; McCrindle BW; Cartoski MJ; Detterich JA; Yetman AT; John AS; Richmond ME; Yung D; Payne RM; Mackie AS; Davis CK; Shahanavaz S; Hill KD; Almaguer M; Zak V; McBride MG; Goldstein BH; Pearson GD; Paridon SM;
Pediatr Cardiol; 2023 Dec; 44(8):1691-1701. PubMed ID: 37382636
[TBL] [Abstract][Full Text] [Related]
2. Results of the FUEL Trial.
Goldberg DJ; Zak V; Goldstein BH; Schumacher KR; Rhodes J; Penny DJ; Petit CJ; Ginde S; Menon SC; Kim SH; Kim GB; Nowlen TT; DiMaria MV; Frischhertz BP; Wagner JB; McHugh KE; McCrindle BW; Shillingford AJ; Sabati AA; Yetman AT; John AS; Richmond ME; Files MD; Payne RM; Mackie AS; Davis CK; Shahanavaz S; Hill KD; Garg R; Jacobs JP; Hamstra MS; Woyciechowski S; Rathge KA; McBride MG; Frommelt PC; Russell MW; Urbina EM; Yeager JL; Pemberton VL; Stylianou MP; Pearson GD; Paridon SM;
Circulation; 2020 Feb; 141(8):641-651. PubMed ID: 31736357
[TBL] [Abstract][Full Text] [Related]
3. Design and rationale of the Fontan Udenafil Exercise Longitudinal (FUEL) trial.
Goldberg DJ; Zak V; Goldstein BH; McCrindle BW; Menon SC; Schumacher KR; Payne RM; Rhodes J; McHugh KE; Penny DJ; Trachtenberg F; Hamstra MS; Richmond ME; Frommelt PC; Files MD; Yeager JL; Pemberton VL; Stylianou MP; Pearson GD; Paridon SM;
Am Heart J; 2018 Jul; 201():1-8. PubMed ID: 29910047
[TBL] [Abstract][Full Text] [Related]
4. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.
Kim KH; Kim HK; Hwang IC; Cho HJ; Je N; Kwon OM; Choi SJ; Lee SP; Kim YJ; Sohn DW
Am Heart J; 2015 Jun; 169(6):813-822.e3. PubMed ID: 26027619
[TBL] [Abstract][Full Text] [Related]
5. Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants.
Di Maria MV; Goldberg DJ; Zak V; Hu C; Lubert AM; Dragulescu A; Mackie AS; McCrary A; Weingarten A; Parthiban A; Goot B; Goldstein BH; Taylor C; Lindblade C; Petit CJ; Spurney C; Harrild DM; Urbina EM; Schuchardt E; Beom Kim G; Kyoung Yoon J; Colombo JN; Files MD; Schoessling M; Ermis P; Wong PC; Garg R; Swanson SK; Menon SC; Srivastava S; Thorsson T; Johnson TR; Krishnan US; Paridon SM; Frommelt PC;
Circ Cardiovasc Imaging; 2022 Nov; 15(11):e013676. PubMed ID: 36378780
[TBL] [Abstract][Full Text] [Related]
6. Exercise Capacity and Predictors of Performance After Fontan: Results from the Pediatric Heart Network Fontan 3 Study.
Goldberg DJ; Zak V; McCrindle BW; Ni H; Gongwer R; Rhodes J; Garofano RP; Kaltman JR; Lambert LM; Mahony L; Margossian R; Spector ZZ; Williams RV; Atz AM; Paridon SM;
Pediatr Cardiol; 2021 Jan; 42(1):158-168. PubMed ID: 32975603
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Udenafil on Heart Rate and Blood Pressure in Adolescents With the Fontan Circulation.
Edelson JB; Zak V; Goldberg D; Fleming G; Mackie AS; Patel JK; Files M; Downing T; Richmond M; Acheampong B; Cartoski M; Detterich J; McCrindle B; McHugh K; Hansen JE; Wagner J; Maria MD; Weingarten A; Nowlen T; Yoon JK; Kim GB; Williams R; Whitehill R; Kirkpatrick E; Yin S; Ermis P; Lubert AM; Stylianou M; Freemon D; Hu C; Garuba OD; Frommelt P; Goldstein BH; Paridon S; Garg R;
Am J Cardiol; 2024 Jan; 210():183-187. PubMed ID: 37918818
[TBL] [Abstract][Full Text] [Related]
8. ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial.
Kim KH; Kim HK; Hwang IC; Lee SP; Cho HJ; Kang HJ; Kim YJ; Sohn DW
Trials; 2013 Jun; 14():188. PubMed ID: 23799908
[TBL] [Abstract][Full Text] [Related]
9. End-Organ Function and Exercise Performance in Patients With Fontan Circulation: What Characterizes the High Performers?
Weinreb SJ; Dodds KM; Burstein DS; Huang J; Rand EB; Mancilla E; Heimall JR; McBride MG; Paridon SM; Goldberg DJ; Rychik J
J Am Heart Assoc; 2020 Dec; 9(24):e016850. PubMed ID: 33317366
[TBL] [Abstract][Full Text] [Related]
10. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial.
Goldberg DJ; French B; McBride MG; Marino BS; Mirarchi N; Hanna BD; Wernovsky G; Paridon SM; Rychik J
Circulation; 2011 Mar; 123(11):1185-93. PubMed ID: 21382896
[TBL] [Abstract][Full Text] [Related]
11. Effect of Fontan geometry on exercise haemodynamics and its potential implications.
Tang E; Wei ZA; Whitehead KK; Khiabani RH; Restrepo M; Mirabella L; Bethel J; Paridon SM; Marino BS; Fogel MA; Yoganathan AP
Heart; 2017 Nov; 103(22):1806-1812. PubMed ID: 28522658
[TBL] [Abstract][Full Text] [Related]
12. Effects of respiratory exchange ratio on the prognostic value of peak oxygen consumption and ventilatory efficiency in patients with systolic heart failure.
Chase PJ; Kenjale A; Cahalin LP; Arena R; Davis PG; Myers J; Guazzi M; Forman DE; Ashley E; Peberdy MA; West E; Kelly CT; Bensimhon DR
JACC Heart Fail; 2013 Oct; 1(5):427-32. PubMed ID: 24621975
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of patients with a relatively greater minimum VE/VCO
Nakade T; Adachi H; Murata M; Oshima S
Eur J Appl Physiol; 2018 Aug; 118(8):1547-1553. PubMed ID: 29761310
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial.
Chang HJ; Song S; Chang SA; Kim HK; Jung HO; Choi JH; Lee JS; Kim KH; Jeong JO; Lee JH; Kim DK
Clin Ther; 2019 Aug; 41(8):1499-1507. PubMed ID: 31202506
[TBL] [Abstract][Full Text] [Related]
15. A Pilot Study of Inspiratory Muscle Training to Improve Exercise Capacity in Patients with Fontan Physiology.
Wu FM; Opotowsky AR; Denhoff ER; Gongwer R; Gurvitz MZ; Landzberg MJ; Shafer KM; Valente AM; Uluer AZ; Rhodes J
Semin Thorac Cardiovasc Surg; 2018 Winter; 30(4):462-469. PubMed ID: 30063966
[TBL] [Abstract][Full Text] [Related]
16. [Cardiopulmonary exercise capacity in adult patients with atrial septal defect].
Suchoń E; Podolec P; Tomkiewicz-Pajak L; Kostkiewicz M; Mura A; Pasowicz M; Tracz W
Przegl Lek; 2002; 59(9):747-51. PubMed ID: 12632902
[TBL] [Abstract][Full Text] [Related]
17. B-type natriuretic peptide kinetics and cardiopulmonary exercise testing in heart failure.
Maeder M; Wolber T; Rickli H; Myers J; Hack D; Riesen W; Weilenmann D; Ammann P
Int J Cardiol; 2007 Sep; 120(3):391-8. PubMed ID: 17182129
[TBL] [Abstract][Full Text] [Related]
18. Sports practice predicts better functional capacity in children and adults with Fontan circulation.
Rato J; Sousa A; Cordeiro S; Mendes M; Anjos R
Int J Cardiol; 2020 May; 306():67-72. PubMed ID: 31785955
[TBL] [Abstract][Full Text] [Related]
19. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction.
Van Tassell BW; Trankle CR; Canada JM; Carbone S; Buckley L; Kadariya D; Del Buono MG; Billingsley H; Wohlford G; Viscusi M; Oddi-Erdle C; Abouzaki NA; Dixon D; Biondi-Zoccai G; Arena R; Abbate A
Circ Heart Fail; 2018 Aug; 11(8):e005036. PubMed ID: 30354558
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy.
Kim HL; Kim YJ; Kim KH; Lee SP; Kim HK; Sohn DW; Oh BH; Park YB
Hypertens Res; 2015 Sep; 38(9):597-604. PubMed ID: 25832922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
